Application of clonal analysis: Differential diagnosis for synchronous primary ovarian and endometrial cancers and metastatic cancer

American Journal of Clinical Pathology

Volumn 105, Issue 3, 1996, Pages 350-359

  Fujita, Masami ^a   Enomoto, Takayuki ^a   Wada, Hiroko ^a   Inoue, Masaki ^b   Okudaira, Yoshio ^a   Shroyer, Kenneth R ^c  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Carcinoma; Clonality; Endometrium; HPV; K ras; Ovary; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM CANCER; FEMALE; GENE LOSS; GENE MUTATION; HUMAN; METASTASIS; ONCOGENE K RAS; OVARY CANCER; PRIORITY JOURNAL; VIRUS DETECTION; WART VIRUS; X CHROMOSOME INACTIVATION;

EID: 0029932462     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/105.3.350     Document Type: Article

References (40)

1. Scully RE. Ovarian tumors: A review. Am J Pathol 1977;87:686-720.
2. Czernobilsky B, Silverman BB, Mikuta JJ. Endometrioid carcinoma of the ovary: A clinicopathologic study of 75 cases. Cancer 1970;26:1141-1152.
3. Zaino RJ, Unger ER, Whitney C. Synchronous carcinomas of the uterine corpus and ovary. Gynecol Oncol 1984;19:329-335.
4. Kline RC, Wharton JT, Atkinson EN, Burke TW, Gerschenson DM, Edwards CL. Endometrioid carcinoma of the ovary: Retrospective review of 145 cases. Gynecol Oncol 1990;39:337-346.
5. Jambhekar NA, Sampat MB. Simultaneous endometrioid carcinoma of the uterine corpus and ovary: A clinicopathologic study of 15 cases. J Surg Oncol 1988;37:20-23.
6. Pearl ML, Johnston CM, Frank TS, Roberts JA. Synchronous dual primary ovarian and endometrial carcinomas. Int J Gynecol Obstet 1993;43:305-312.
7. Ayhan A, Yalçin Ö, Selçuk Tuncer Z, Gürgan T, Kücükali T. Synchronous primary malignancies of the female genital tract. Eur J Obstet Gynecol Reprod Biol 1992;45:63-66.
8. Tidy J, Mason WP. Endometrioid carcinoma of the ovary: A retrospective study. Br J Obstet Gynecol 1988;95:1165-1169.
9. Eifel P, Hendrickson M, Ross J, Ballon S, Martinez A, Kempson R. Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer 1982;50:163-170.
10. Warren S, Gates O. Multiple primary tumors: A survey of the literature and a statistical study. Am J Cancer 1932;16:1358-1414.
11. Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: A clinicopathologic study of 34 cases. Hum Pathol 1985;16:28-34.
12. Symonds DA, Johnson DP, Wheeless CR. Feulgen cytometry in simultaneous endometrial and ovarian carcinoma. Cancer 1988;61:2511-2516.
13. Prat J, Matias-Guiu X, Barreto J. Simultaneous carcinoma involving the endometrium and the ovary: A clinicopathologic, immunohistochemical, and DNA flow cytometric study of 18 cases. Cancer 1991;68:2455-2459.
14. Poulsen HE, Taylor CW, Sobin LH. Histological typing of female genital tract tumors. In: International Histological Classification of Tumors, No. 13, Geneva: World Health Organization, 1975, pp 63-73.
15. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of Hpa II and Hha I sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inacttvation. Am J Hum Genet 1992;51: 1229-1239.
16. Enomoto T, Fujita M, Inoue M, et al. Analysis of clonality by amplification of short tandem repeats: Carcinomas of the female reproductive tract. Diag Mol Pathol 1994;3:292-297.
17. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 1992;52:5323-5328.
18. Fujita M, Enomoto T, Inoue M, et al. Alterations of the p53 tumor suppressor gene occurs independently of K.-ra.s activation and more frequently inserous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 1994;85:1247-1256.
19. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988;70:245-252.
20. Meltzer SJ, Yin J, Huang Y, et al. Reduction to homozygosity involving p53 in esophageal cancers. ProNail Acad Sci USA 1991;88:4976-4980.
21. Enomoto T, Fujita M, Inoue M, et al. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 1993;53:1883-1888.
22. Enomoto T, Inoue M, Perantoni AO, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991;51:5308-5314.
23. Southern EM. Detection of specific sequences among DNA frag-ments separated by gel electrophoresis. J Mol Biol 1978;98:503-517.
24. Fujita M, Shroyer KR, Markham NE, et al. Association of human papillomavirus with malignant and premalignant lesions of the uterine endometrium. Hum Pathol 1995;26:650-658.
25. Vogelstein B, Fearon ER, Hamilton SR, Feinbeig AP. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science 1985;227:642-645.
26. Gilliland DO, Blanchard KL, Levy J, Perrin S Bunn HF. Clonality in myeloproliferative disorders: analysis by means of polymer-ase chain reaction. Proc Nail Acad Sci USA 1991;88:6848-6852.
27. Shroyer KR, Gudlaugsson E. Determination of clonality in endometrial carcinoma by PCR amplification of PGK-I. Hum Pathol 1994;25:287-292.
28. Barr ML, Bertram EG. A morphological distinction between neurones of the male and female, and the behaviour of the nucleolar satellite during accelerated nucleoprotein synthesis. Nature 1949;163:676-677.
29. Gartler SM, Riggs AD. Mammalian X-chromosome inactivation. Ann Rev Genet 1938;17:155-190.
30. Wolf SF, Jolly DJ, Lunnen KD, Friedmann T, Migeon BR. Methylation of the hypoxanthine phosphoribosyl-transferase locus on the human X-chromosome: implications for X-chromosome inactivation. Proc Nail Acad Sci USA 1984;81:2806-2810.
31. Riggs AD. X inactivation, differentiation, and DNA methylation. Cytogenet Cell Genet 1975;14:135-148.
32. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689.
33. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-456.
34. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989;342:705-708.
35. Enomoto T, Inoue M, Perantoni AO, et al. K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 1990;50:6139-6145.
36. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991;139:777-785.
37. Okamoto A, Sameshima Y, Yokoyama S, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991;51:5171-5176.
38. Teneriello MG, Ebina M, Linnoila RI, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53: 3103-3108.
39. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-1519.
40. Jacobs IJ, Kohler MF, Wisemen RW, et al. Clonal origin of epithelial carcinoma: Analysis by loss of heterzygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992;84: 1793-1798.